Linked Life Data

15285725

Source:http://linkedlifedata.com/resource/pubmed/id/15285725

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15285725rdf:typepubmed:Citationlld:pubmed
pubmed-article:15285725lifeskim:mentionsumls-concept:C0005821lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C1179435lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C0037633lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C1521827lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C1698986lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C1705248lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C1382100lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C2349200lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C0442796lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C1548799lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C1524073lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C2348767lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C0449432lld:lifeskim
pubmed-article:15285725lifeskim:mentionsumls-concept:C1709595lld:lifeskim
pubmed-article:15285725pubmed:issue4lld:pubmed
pubmed-article:15285725pubmed:dateCreated2004-8-2lld:pubmed
pubmed-article:15285725pubmed:abstractTextDespite the introduction of platelet additive solutions for the preparation of pooled platelet components, only a few studies of limited scope have evaluated the clinical efficacy of platelets stored in these solutions. The current report presents an analysis of data to evaluate the response to the transfusion of pooled buffy-coat components suspended in storage solution with reduced (35%) plasma content in comparison with 100% plasma products. During the euroSPRITE clinical trial of platelet components treated with a pathogen inactivation process, control treatment group platelet components were prepared in 100% allogeneic donor plasma (plasma control) or in platelet additive solution (T-Sol) mixed with plasma (T-Sol control). Control group thrombocytopenic patients received either plasma control or T-Sol control platelet components. One-hour and 24-h platelet count increments (CIs) and corrected count increments (CCIs) were analysed for these two types of preparation. In addition, haemostatic assessments were conducted for each transfusion. One-hour and 24-h mean platelet CIs and post-transfusion haemostatic scores were not significantly different for patients receiving platelet components suspended in 100% plasma and T-Sol plasma mixtures. Pooled buffy-coat platelet components prepared in reduced plasma content mixtures provided therapeutic platelet CIs with effective haemostasis.lld:pubmed
pubmed-article:15285725pubmed:languageenglld:pubmed
pubmed-article:15285725pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15285725pubmed:citationSubsetIMlld:pubmed
pubmed-article:15285725pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15285725pubmed:statusMEDLINElld:pubmed
pubmed-article:15285725pubmed:monthAuglld:pubmed
pubmed-article:15285725pubmed:issn0958-7578lld:pubmed
pubmed-article:15285725pubmed:authorpubmed-author:DavisKKlld:pubmed
pubmed-article:15285725pubmed:authorpubmed-author:FlamentJJlld:pubmed
pubmed-article:15285725pubmed:authorpubmed-author:CorashLLlld:pubmed
pubmed-article:15285725pubmed:authorpubmed-author:CazenaveJ PJPlld:pubmed
pubmed-article:15285725pubmed:authorpubmed-author:van RhenenD...lld:pubmed
pubmed-article:15285725pubmed:authorpubmed-author:GullikssonHHlld:pubmed
pubmed-article:15285725pubmed:authorpubmed-author:PamphilonDDlld:pubmed
pubmed-article:15285725pubmed:issnTypePrintlld:pubmed
pubmed-article:15285725pubmed:volume14lld:pubmed
pubmed-article:15285725pubmed:ownerNLMlld:pubmed
pubmed-article:15285725pubmed:authorsCompleteYlld:pubmed
pubmed-article:15285725pubmed:pagination289-95lld:pubmed
pubmed-article:15285725pubmed:dateRevised2008-7-31lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:meshHeadingpubmed-meshheading:15285725...lld:pubmed
pubmed-article:15285725pubmed:year2004lld:pubmed
pubmed-article:15285725pubmed:articleTitleTherapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.lld:pubmed
pubmed-article:15285725pubmed:affiliationSanquin Blood Bank South-west Region, Rotterdam, The Netherlands. dick.van.rhenen@bloodrtd.nllld:pubmed
pubmed-article:15285725pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15285725pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15285725pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15285725pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:15285725pubmed:publicationTypeMulticenter Studylld:pubmed